284 related articles for article (PubMed ID: 23666680)
1. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
2. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.
Kortekaas KA; Hoogslag GE; de Boer RA; Dokter MM; Versteegh MI; Braun J; Marsan NA; Verwey HF; Delgado V; Schalij MJ; Klautz RJ
Eur J Heart Fail; 2013 Sep; 15(9):1011-8. PubMed ID: 23576289
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
Lok DJ; Lok SI; Bruggink-André de la Porte PW; Badings E; Lipsic E; van Wijngaarden J; de Boer RA; van Veldhuisen DJ; van der Meer P
Clin Res Cardiol; 2013 Feb; 102(2):103-10. PubMed ID: 22886030
[TBL] [Abstract][Full Text] [Related]
5. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.
de Boer RA; Lok DJ; Jaarsma T; van der Meer P; Voors AA; Hillege HL; van Veldhuisen DJ
Ann Med; 2011 Feb; 43(1):60-8. PubMed ID: 21189092
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs are associated with cardiac biomarkers, cardiac structure and function and incident outcomes in heart failure.
Spahillari A; Jackson L; Varrias D; Michelhaugh SA; Januzzi JL; Shahideh B; Daghfal D; Valkov N; Murtagh G; Das S
ESC Heart Fail; 2024 Jun; 11(3):1400-1410. PubMed ID: 38321808
[TBL] [Abstract][Full Text] [Related]
9. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J
Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
Gaggin HK; Szymonifka J; Bhardwaj A; Belcher A; De Berardinis B; Motiwala S; Wang TJ; Januzzi JL
JACC Heart Fail; 2014 Feb; 2(1):65-72. PubMed ID: 24622120
[TBL] [Abstract][Full Text] [Related]
11. The effects of short-term omission of daily medication on the pathophysiology of heart failure.
Dovancescu S; Pellicori P; Mabote T; Torabi A; Clark AL; Cleland JGF
Eur J Heart Fail; 2017 May; 19(5):643-649. PubMed ID: 28295907
[TBL] [Abstract][Full Text] [Related]
12. Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure.
Zhang T; Shao B; Liu GA
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4406-4410. PubMed ID: 29077153
[TBL] [Abstract][Full Text] [Related]
13. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
[TBL] [Abstract][Full Text] [Related]
14. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
[TBL] [Abstract][Full Text] [Related]
15. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
17. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure.
Lala RI; Lungeanu D; Darabantiu D; Pilat L; Puschita M
Herz; 2018 Mar; 43(2):146-155. PubMed ID: 28235980
[TBL] [Abstract][Full Text] [Related]
19. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
20. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure.
Motiwala SR; Gaggin HK; Gandhi PU; Belcher A; Weiner RB; Baggish AL; Szymonifka J; Januzzi JL
J Cardiovasc Transl Res; 2015 Apr; 8(3):164-72. PubMed ID: 25777344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
